CervoMed’s Promising Phase 2b Trial Results for DLB

CervoMed ( (CRVO) ) has provided an announcement.

CervoMed announced new data from its Phase 2b RewinD-LB trial, presented at the 18th Clinical Trials on Alzheimer’s Disease Conference in December 2025, showing that neflamapimod treatment led to improvements in neuroinflammation and neurodegeneration markers in patients with dementia with Lewy bodies. The trial demonstrated significant reductions in plasma GFAP levels and an increase in the Ab42/40 ratio, suggesting that neflamapimod may act on the underlying disease process. These findings reinforce previous studies and support the initiation of a Phase 3 trial, highlighting the potential impact on treatment options for DLB, a condition with no approved treatments in the US or EU.

The most recent analyst rating on (CRVO) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on CervoMed stock, see the CRVO Stock Forecast page.

Spark’s Take on CRVO Stock

According to Spark, TipRanks’ AI Analyst, CRVO is a Neutral.

CervoMed’s primary challenges stem from its lack of revenue and persistent financial losses, which heavily weigh down its stock score. However, positive technical indicators and recent promising clinical trial results provide a speculative upside, balancing some of the financial concerns. Valuation remains a challenge due to negative earnings, but the potential for future success in clinical trials offers hope for long-term growth.

To see Spark’s full report on CRVO stock, click here.

More about CervoMed

CervoMed is a clinical-stage biotechnology company focused on developing treatments for age-related brain disorders. Its lead drug candidate, neflamapimod, is designed to target neuroinflammation and neurodegeneration, particularly in conditions like dementia with Lewy bodies (DLB).

Average Trading Volume: 95,239

Technical Sentiment Signal: Sell

Current Market Cap: $83.83M

For a thorough assessment of CRVO stock, go to TipRanks’ Stock Analysis page.